Current Research and Development Initiatives

  • Human T Lymphotropic Virus Type I (HTLV-I) induced DNA synthesis (HAM TSP).
  • MxA protein mRNA assay (bioavailabilty of Interferon-beta in the presence of intermediate levels of Neutralizing Antibodies).
  • Affinity/Binding measures of antigen/antibody interactions using BIAcore (antibody screening).
  • Anti-muscle specific tyrosine kinase (anti-MuSK) antibody (myasthenia gravis).
  • Anti-aquaporin-4 antibody (neuromyelitis optica and related conditions)
  • Anti-natalizumab (Tysabri®) antibody (multiple sclerosis)

Select Publications

Late-onset myasthenia gravis: A review when incidence in older adults keeps increasing. Alkhawajah NM, Oger J. Muscle Nerve. 2013 Nov;48(5):705-10. doi: 10.1002/mus.23964.

Interferon beta and long-term disability in multiple sclerosis. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. JAMA Neurol. 2013 May;70(5):651-2. doi: 10.1001/jamaneurol.2013.2197. No abstract available.

DMDs Are an Essential Issue But Are They the Only Issue in MS Treatment? Shahbeigi S, Oger J. Can J Neurol Sci. 2013 May;40(3):276-7. No abstract available.

Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories. Shahkarami MA, Vaziri B, Salami S, Harandi AA, Oger J. J Immunol Methods. 2013 Feb 28;388(1-2):46-8. doi: 10.1016/j.jim.2012.11.013. Epub 2012 Dec 6.

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. Goodin DS, Ebers GC, Cutter G, Cook SD, O’Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V. BMJ Open. 2012 Nov 30;2(6). doi:pii: e001972. 10.1136/bmjopen-2012-001972. Print 2012.

Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know! Alkhawajah MM, Caminero AB, Freeman HJ, Oger JJ. Mult Scler. 2013 Mar;19(3):259-65. doi: 10.1177/1352458512461393. Epub 2012 Oct 1. Review.

Insights into origins of Human T-cell Lymphotropic Virus Type 1 based on new strains from aboriginal people of Canada. Andonov A, Coulthart MB, Pérez-Losada M, Crandall KA, Posada D, Padmore R, Giulivi A, Oger JJ, Peters AA, Dekaban GA.  Infect Genet Evol. 2012 Dec;12(8):1822-30. doi: 10.1016/j.meegid.2012.07.015. Epub 2012 Aug 13.

‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study. Leray E, Coustans M, Le Page E, Yaouanq J, Oger J, Edan G. Mult Scler. 2013 Apr;19(4):458-65.

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625.

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. Neurology. 2012 Apr 24;78(17):1315-22.

Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Pakzad Z, Aziz T, Oger J. Neurology. 2011 Apr 26;76(17):1526-8

Frequency and Magnitude of Interferon β Neutralizing Antibodies in the Evaluation of Interferon β Immunogenicity in Patients with Multiple Sclerosis. Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP. J Interferon Cytokine Res. 2011 Jan 12.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Lancet Neurol. 2010 Jul;9(7):740-50

CCSVI: hope, hype or snake oil? Oger J, Alkhawajah M. Can J Neurol Sci. 2010 Nov;37(6):716. No abstract available. Erratum in: Can J Neurol Sci. 2011 Mar;38(2):379. Alkhajawah, Mona [corrected to Alkhawajah, Mona]

Where are we going with drugs to treat MS? Will cost continue to increase? Oger J, AlKhawajah M. Can J Neurol Sci. 2010 May;37(3):305-8.

Evidence for a two-stage disability progression in multiple sclerosis. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G. Brain. 2010 Jul;133(Pt 7):1900-13

Adult celiac disease with acetylcholine receptor antibody positive myasthenia gravis. Freeman HJ, Gillett HR, Gillett PM, Oger J. World J Gastroenterol. 2009 Oct 14;15(38):4741-4

A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. Gibbs E, Oger J. J Interferon Cytokine Res. 2008 Dec;28(12):713-23

Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J. J Immunol Methods. 2008 Jul 31;336(2):113-8.

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Boz C, Oger J, Gibbs E, Grossberg SE; Neurologists of the UBC MS Clinic. Mult Scler. 2007 Nov;13(9):1127-37.

The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. Gibbs E, Oger J. J Neuroimmunol. 2007 Oct;190(1-2):146-50

HTLV-1 infection and the viral etiology of multiple sclerosis. Oger J. J Neurol Sci. 2007 Nov 15;262(1-2):100-4

Occurrence of CNS demyelinating disease in patients with myasthenia gravis.Kister I, Herbert J, Swerdlow ML, Bergamaschi R, Piccolo G, Oger J. Neurology. 2007 Apr 17;68(16):1326-7

Immunosuppression in MS: promises and failures. Oger J.J Neurol Sci. 2007 Aug 15;259(1-2):74-8